GLP1R and obesity due to melanocortin 4 receptor deficiency: The findings align with previous studies that indicated GLP-1 RAs are prescribed primarily because of their action to reduce blood sugar and help with weight loss.[5] Nonetheless, the proportionally lower percentage of patients using these drugs for obesity-related disease prevention indicates a shortfall in patient education on their general benefits beyond diabetes control.[19]